Innate Pharma

Innate Pharma announces its financial calendar for 2017

January 4, 2017

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2017, which is set as follows: March 7, 2017 : Publication of 2016 financial statements...

Outcome of Innate Pharma’s 2026 Annual General Meeting

May 22, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 21...

Innate Pharma to participate in the Jefferies Global Healthcare Conference

May 19, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that...

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

May 13, 2026

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation...

Number of shares and voting rights of Innate Pharma as of April 16, 2026

May 12, 2026

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...

Innate Pharma announces conference call and webcast for Q1 2026 Business Update

May 6, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a...

Innate Pharma to participate in the D. Boral Capital Global Conference

April 23, 2026

Innate Pharma to present MATISSE Phase 2 interim results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

April 17, 2026

Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and...

Innate Pharma to hold its annual general meeting of shareholders on May 21, 2026

April 13, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of shareholders (“ AGM ”) at 10:30 a.m. CEST on May 21, 2026, at its...

Number of shares and voting rights of Innate Pharma as of April 9, 2026

April 13, 2026